IL313361A - Combined treatment that includes a fax inhibitor and a c-met inhibitor - Google Patents

Combined treatment that includes a fax inhibitor and a c-met inhibitor

Info

Publication number
IL313361A
IL313361A IL313361A IL31336124A IL313361A IL 313361 A IL313361 A IL 313361A IL 313361 A IL313361 A IL 313361A IL 31336124 A IL31336124 A IL 31336124A IL 313361 A IL313361 A IL 313361A
Authority
IL
Israel
Prior art keywords
inhibitor
combination therapy
pkc
met
met inhibitor
Prior art date
Application number
IL313361A
Other languages
English (en)
Hebrew (he)
Inventor
Jaymes Holland
Sarah Shwu-Kuan Jaw-Tsai
Mai Hope Le
Anthony Maurer Matthew
Michael Gabriel O'quigley
Richard Zang
Original Assignee
Ideaya Biosciences Inc
Pfizer
Jaymes Holland
Jaw Tsai Sarah Shwu Kuan
Mai Hope Le
Anthony Maurer Matthew
Oquigley Michael Gabriel
Richard Zang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc, Pfizer, Jaymes Holland, Jaw Tsai Sarah Shwu Kuan, Mai Hope Le, Anthony Maurer Matthew, Oquigley Michael Gabriel, Richard Zang filed Critical Ideaya Biosciences Inc
Publication of IL313361A publication Critical patent/IL313361A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL313361A 2021-12-06 2022-12-05 Combined treatment that includes a fax inhibitor and a c-met inhibitor IL313361A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163286345P 2021-12-06 2021-12-06
US202263317573P 2022-03-08 2022-03-08
US202263370056P 2022-08-01 2022-08-01
PCT/US2022/080928 WO2023107894A1 (en) 2021-12-06 2022-12-05 Combination therapy comprising a pkc inhibitor and a c-met inhibitor

Publications (1)

Publication Number Publication Date
IL313361A true IL313361A (en) 2024-08-01

Family

ID=86731264

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313361A IL313361A (en) 2021-12-06 2022-12-05 Combined treatment that includes a fax inhibitor and a c-met inhibitor

Country Status (8)

Country Link
US (1) US20240335440A1 (https=)
EP (1) EP4444303A4 (https=)
JP (1) JP2024542831A (https=)
AU (1) AU2022407330A1 (https=)
CA (1) CA3239676A1 (https=)
IL (1) IL313361A (https=)
MX (1) MX2024006948A (https=)
WO (1) WO2023107894A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014174478A1 (en) * 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US11413284B2 (en) * 2017-09-12 2022-08-16 Novartis Ag Protein kinase C inhibitors for treatment of uveal melanoma
AU2020386903A1 (en) * 2019-11-18 2022-06-09 Ideaya Biosciences, Inc. Dosing regimens for a protein kinase C inhibitor
JP2023541011A (ja) * 2020-09-08 2023-09-27 イデアヤ、バイオサイエンシズ、インコーポレイテッド 医薬組み合わせおよび腫瘍治療

Also Published As

Publication number Publication date
CA3239676A1 (en) 2023-06-15
EP4444303A4 (en) 2025-11-26
EP4444303A1 (en) 2024-10-16
AU2022407330A1 (en) 2024-07-04
US20240335440A1 (en) 2024-10-10
WO2023107894A1 (en) 2023-06-15
JP2024542831A (ja) 2024-11-15
MX2024006948A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
IL283598A (en) Combined treatment with radio-immune conjugates and a checkpoint inhibitor
IL313727A (en) Parfee inhibitors
EP4322953A4 (en) COMBINATION THERAPY WITH A PKC INHIBITOR AND A MEK INHIBITOR
IL312886A (en) Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor
IL316750A (en) Treatments with Nirogesstat
PL4094763T3 (pl) Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem
ZA202210488B (en) Therapeutic lighting devices and methods
IL313361A (en) Combined treatment that includes a fax inhibitor and a c-met inhibitor
IL304223A (en) combined treatment
IL309243A (en) Radioimmunoconjugates and combination therapy with barrier surveillance
GB202104037D0 (en) Combination therapy
IL318268A (en) Combined treatment
GB202111288D0 (en) Combination therapy
EP4185295A4 (en) Combination therapy of parp inhibitors
IL325938A (en) Combination therapy including BTK inhibitor and BELUMOSUDIL
EP4087561A4 (en) CANCER COMBINATION THERAPY USING A CHK INHIBITOR
GB202408599D0 (en) Combination treatments
GB202408598D0 (en) Combination treatments
CA3304829A1 (en) Combination therapy with a parg inhibitor
GB202505461D0 (en) New combination treatments
HK40109325A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
GB2610223B (en) A plug head and a combination comprising a plug head
GB202208911D0 (en) Treatments
GB202016955D0 (en) Therapeutic treatments
HK40072363A (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor